Neoleukin Therapeutics (NLTX) Prices 3.26M Share Common Offering at $15.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
After-Hours Stock Movers 7/1: (VERO) (NUS) (FORM) Higher; (CULP) (ZOM) (BLFS) Lower (more...)
July 1, 2020 5:29 PM EDTToday's After-Hours Stock Movers
Venus Concept (NASDAQ: VERO) 56.2% HIGHER; today announced that it has received FDA 510(k) clearance to market and sell Venus Viva MD. Venus Viva MD is a non-invasive device intended to be used by aesthetic-related physicians or dermatologists. It expands the Companys skin rejuvenation offerings beyond the Venus Viva and Venus Versa which were introduced to the medical aesthetics market in 2015 and 2016, respectively.
Culp, Inc. (NYSE: CULP) 19.2% LOWER; reported Q3 EPS of ($2.26), versus ($0.12) reported last... More
Neoleukin Therapeutics (NLTX) Announces 5M Share Proposed Public Offering
July 1, 2020 4:02 PM EDTNeoleukin Therapeutics, Inc. (Neoleukin) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its... More
